Go <> No-Go in Early Life Science and MedTech Investments

• Venture-Caliber Diligence

We provide the technical and business diligence to ensure a start-up’s realities match your investment vision.

• Clinical Translation and Investment Readiness

For academic leaders allocating constrained capital, we identify, evaluate, and develop raw discoveries best suited for translation and commercialization.

• Fiduciary Governance and Special Situations

When portfolio companies face critical transitions or strategic hurdles, we provide the active governance and hands-on leadership needed to protect equity.

See recent diligence notes and presentations on capital risks facing both sides of the table.

Inquiries regarding advisory availability may be directed to
jyounger@argopond.com.

Active Engagements

Autumn 2026 briefings, panels, and investment forums.

Philadelphia (Sept 10) / Healthcare and Life Sciences Capital Stack / Alliance Bernstein
New York (Oct 1) / VC Co-Working Day: Healthcare and Therapeutics / SOSV New York
Boston (Oct 18–21) / MedTech Investment Working Group / AdvaMed
Bethesda (Nov 30) / Investor Readiness Forum / NIH Blueprint MedTech

Fiduciary & Diligence Footprint

A ten-year record of strategic counsel, boardroom governance, and capital de-risking.

North America

Corporate & Private Capital
Akadeum Life Sciences / New View Surgical / Immune Functional Diagnostics / Silverstein Properties / Life Sciences Greenhouse Investments / IAG Capital Partners / 1315 Capital
Federal & Public Policy
United States House Committee on Small Business (Testimony) / National Institutes of Health / National Science Foundation
Health Systems & Academia
University of Pennsylvania / Children’s Hospital of Philadelphia / Monroe Carell Jr. Children’s Hospital at Vanderbilt / University of Michigan / University of Minnesota / Drexel University

Europe

Corporate & Private Capital
Cilcare Therapeutics

Asia

Health Systems & Academia
Duke National University of Singapore